Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous hemodiafiltration: A patient case and literature review.

08:00 EDT 18th March 2020 | BioPortfolio

Summary of "Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous hemodiafiltration: A patient case and literature review."

No Summary Available


Journal Details

This article was published in the following journal.

Name: Journal of global antimicrobial resistance
ISSN: 2213-7173


DeepDyve research library

PubMed Articles [30665 Associated PubMed Articles listed on BioPortfolio]

Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.

 New treatments are needed for multidrug-resistant (MDR) gram-negative infections in neonates. Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination that has broad-spectrum activi...

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Infections in Saudi Tertiary Care Center.

Multidrug-resistant isolates have multiple resistance mechanisms, and there are insufficient therapeutic options to target them. Ceftolozane-tazobactam is a novel antipseudomonal agent that contains ...

Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.

The clinical use, safety and effectiveness of ceftolozane/tazobactam among 13 patients 3 months to 19 years of age infected with multidrug-resistant Pseudomonas aeruginosa are described. All but one p...

In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).

The Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution testing method (M07, 11th edition, 2018) was used to determine MICs for ceftolozane/tazobactam and eight comparator a...

In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study.

Our objective was to compare the activity of ceftazidime-avibactam (C/A), ceftolozane-tazobactam (C/T) and 3 anti-pseudomonal beta-lactams (piperacillin-tazobactam, ceftazidime, cefepime) against a co...

Clinical Trials [18701 Associated Clinical Trials listed on BioPortfolio]

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a single intravenous dose of ceftolozane/tazobactam in pediatric participants. Ceftolozane/tazobac...

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Ceftolozane/Tazobactam is a newly a...

Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

This study will help provide information about how patients with burn handle two antibiotics (ceftolozane and tazobactam) and use that information to guide dosing recommendations for these...

Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients

The aim of this study is to determine the Ceftolozane-Tazobactam Plasmatic Levels and and analyse the clinical impact that might have the dose regimens that have been used until now.

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality...

Medical and Biotech [MESH] Definitions

Two populations of Zucker rats have been cited in research--the "fatty" or obese and the lean. The "fatty" rat (Rattus norvegicus) appeared as a spontaneous mutant. The obese condition appears to be due to a single recessive gene.

An approach or process of practicing oral health care that requires the judicious integration of systematic assessments of clinical relevant scientific evidence, relating to the patient's oral and medical condition and history, with the dentist's clinical expertise and the patient's treatment needs and preferences. (from J Am Dent Assoc 134: 689, 2003)

A child who is receiving long-term in-patient services or who resides in an institutional setting.

An adolescent who is receiving long-term in-patient services or who resides in an institutional setting.

Work that consists of a conference of physicians on their observations of a patient at the bedside, regarding the physical state, laboratory and other diagnostic findings, clinical manifestations, results of current therapy, etc. A clinical conference usually ends with a confirmation or correction of clinical findings by a pathological diagnosis performed by a pathologist. "Clinical conference" is often referred to as a "clinico-pathological conference."

Quick Search

DeepDyve research library

Relevant Topic

Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

Searches Linking to this Article